Delivery Order SPE2DB24D2101-SPE2DB25FKPPC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count units) under a firm fixed-price contract. The order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,575.75 for IMBRUVICA 140 mg tablets (28-count supply) on August 28, 2025, with completion scheduled for September 19, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of Imbruvica 280 mg tablets (28-count units) on September 4, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $15,151.52 on August 15, 2025, for the supply of Imbruvica 280 mg tablets (quantity: 28 units) under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The order is non-set-aside and competitively awarded, with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count package), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed from the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for IMBRUVICA 280 mg tablets (28-count) under a firm fixed-price contract valued at $7,575.75, with performance completion targeted for August 25, 2025. This competitive award carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of IMBRUVICA 420 mg tablets (28-count packages) with a ceiling value of $15,151.52. This is a firm fixed-price delivery order with an ultimate completion date of October 1, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) with a ceiling value of $7,575.75. This firm fixed-price delivery order represents a non-set-aside award issued through competitive procurement. The contract is scheduled for ultimate completion by September 24, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $7,575.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPPCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $30,303.04 to AmerisourceBergen Drug Corp for 28 tablets of Imbruvica 420 mg on September 15, 2025, with completion targeted for October 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Imbruvica is a prescription medication used to treat certain blood cancers and lymphoid malignancies, representing the type of specialty pharmaceutical supply that supports military and veteran healthcare systems. This delivery order is a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this comprehensive global pharmaceutical support vehicle. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical supply requirements across therapeutic domains, from specialty medications to vaccines and medical devices, supporting military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.3k | 9/15/25 |